1. Search Result
Search Result
Results for "

HT1

" in MedChemExpress (MCE) Product Catalog:

384

Inhibitors & Agonists

1

Screening Libraries

2

Peptides

7

Natural
Products

43

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0607
    Nitisinone
    2 Publications Verification

    NTBC; Nitisone; SC0735

    HPPD Metabolic Disease
    Nitisinone is an orally active, competitive and reversible 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor with an IC50 of 173 nM. Nitisinone promotes tyrosine accumulation in a dose-dependent manner. nitisinone can be used in studies of hereditary tyrosinemia type 1 (HT-1) (a rare genetic disorder) and albinism [1] .
    Nitisinone
  • HY-B0206

    MK 462

    5-HT Receptor Neurological Disease
    Rizatriptan benzoate (Maxalt) is a 5-HT1 agonist.
    Rizatriptan benzoate
  • HY-B0197A
    Naratriptan hydrochloride
    2 Publications Verification

    GR-85548A hydrochloride

    5-HT Receptor Neurological Disease
    Naratriptan hydrochloride is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches.
    Naratriptan hydrochloride
  • HY-101583

    SPI-376

    5-HT Receptor GABA Receptor Dopamine Receptor Neurological Disease
    NEO 376 is a selective modulator of 5-HT1 receptor, GABA receptor and dopamine receptor, with anti-psychotic actively.
    NEO 376
  • HY-B0607R

    NTBC (Standard); Nitisone (Standard); SC56735 (Standard)

    HPPD Metabolic Disease
    Nitisinone (Standard) is the analytical standard of Nitisinone. This product is intended for research and analytical applications. Nitisinone is an orally active, competitive and reversible 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor with an IC50 of 173 nM. Nitisinone promotes tyrosine accumulation in a dose-dependent manner. nitisinone can be used in studies of hereditary tyrosinemia type 1 (HT-1) (a rare genetic disorder) and albinism [1] .
    Nitisinone (Standard)
  • HY-B0197

    GR-85548A

    5-HT Receptor Neurological Disease
    Naratriptan is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches.
    Naratriptan
  • HY-B0197AS

    GR-85548A d3

    Isotope-Labeled Compounds 5-HT Receptor Neurological Disease
    Naratriptan-d3 (hydrochloride) is the deuterium labeled Naratriptan, which is a selective 5-HT1 receptor subtype agonist.
    Naratriptan-d3 hydrochloride
  • HY-19578A

    (±)-Isamoltane hydrochloride

    Others Neurological Disease
    Isamoltan ((±)-Isamoltane) hydrochloride is a serotonin 5-HT1 receptor antagonist, which exhibits significant biological activity in pharmacological applications.
    Isamoltan hydrochloride
  • HY-106124

    5-HT Receptor Cardiovascular Disease
    IS-159 is a potent serotonin 5-HT1 agonist. IS-159 has the potential for the research of migraine [1].
    IS-159
  • HY-B0197S

    GR-85548A-d3-1

    5-HT Receptor Neurological Disease
    Naratriptan-d3 is the deuterium labeled Naratriptan[1]. Naratriptan is a selective 5-HT1 receptor subtype agonist[2].
    Naratriptan-d3
  • HY-B0206R

    MK 462 (Standard)

    5-HT Receptor Neurological Disease
    Rizatriptan (benzoate) (Standard) is the analytical standard of Rizatriptan (benzoate). This product is intended for research and analytical applications. Rizatriptan benzoate (Maxalt) is a 5-HT1 agonist.
    Rizatriptan benzoate (Standard)
  • HY-B0206S

    Isotope-Labeled Compounds 5-HT Receptor Neurological Disease
    Rizatriptan-d6 (benzoate) is the deuterium labeled Rizatriptan benzoate. Rizatriptan benzoate is a 5-HT1 agonist triptan agent for the treatment of migraine headaches[1][2].
    Rizatriptan-d6 benzoate
  • HY-15688
    8-OH-DPAT hydrobromide
    2 Publications Verification

    8-Hydroxy-DPAT hydrobromide

    5-HT Receptor Neurological Disease
    8-OH-DPAT (8-Hydroxy-DPAT) hydrobromide is a potent and selective 5-HT1A agonist with a pIC50 of 8.19. 8-OH-DPAT hydrobromide has selectivity of almost 1000 fold for a subtype of the 5-HT1 binding site [1].
    8-OH-DPAT hydrobromide
  • HY-B2089

    5-HT Receptor Dopamine Receptor Neurological Disease Metabolic Disease
    Cinitapride is a nonselective 5-HT1 and 5-HT4 receptors agonist and a 5-HT2 and D2 antagonist. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research [1].
    Cinitapride
  • HY-135021

    5-HT Receptor Others
    3,4-Dihydro Naratriptan is a serotonin 5-HT1-receptor agonist. 3,4-Dihydro Naratriptan exhibits selective vasoconstrictor activity. 3,4-Dihydro Naratriptan can be used for migraine diseases research [1].
    3,4-Dihydro Naratriptan
  • HY-B0121B
    Sumatriptan
    3 Publications Verification

    GR 43175 free base

    5-HT Receptor Neurological Disease
    Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research [1] .
    Sumatriptan
  • HY-B0121A

    GR 43175 hydrochloride

    5-HT Receptor Neurological Disease
    Sumatriptan hydrochloride (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan hydrochloride can be used for migraine headache research [1] .
    Sumatriptan hydrochloride
  • HY-106805

    5-HT Receptor Others
    ICI 169369 is an orally active, specific serotonin and 5-HT2/5-HT1C receptor competitive antagonist. ICI 169369 exhibits Ki values of 1.79 x 10− 8 and 1.58 x 10− 6 M for 5-HT2 and 5-HT1, respectively [1] .
    ICI 169369
  • HY-B0121BS

    GR 43175C-d6

    5-HT Receptor Isotope-Labeled Compounds Neurological Disease
    Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research [1] .
    Sumatriptan-d6 succinate
  • HY-B0121
    Sumatriptan succinate
    3 Publications Verification

    GR 43175 succinate

    5-HT Receptor Neurological Disease
    Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan succinate can be used for migraine headache research [1] .
    Sumatriptan succinate
  • HY-106484

    BAY-P 4495

    5-HT Receptor Neurological Disease
    Tiflucarbine (BAY-P 4495) is a tetrahydrothieno-7-carboline derivative. Tiflucarbine is a potent antidepressant agent that binds at central serotonin (5-HT) binding sites. Tiflucarbine is a nonselective 5-HT (5-HT1 and 5-HT2) agonist [1] .
    Tiflucarbine
  • HY-44132

    RS 42358-197

    5-HT Receptor Neurological Disease
    Dehydro Palonosetron (RS 42358-197) is a potent, seslective and orally active 5-HT3 receptor antagonist. Dehydro Palonosetron has no effect on the activities of 5-HT1 receptors, 5-HT2 receptors or 5-HT4 receptors [1].
    Dehydro Palonosetron
  • HY-B0121R

    GR 43175 succinate (Standard)

    5-HT Receptor Neurological Disease
    Sumatriptan (succinate) (Standard) is the analytical standard of Sumatriptan (succinate). This product is intended for research and analytical applications. Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research [1] .
    Sumatriptan succinate (Standard)
  • HY-B2089R

    5-HT Receptor Dopamine Receptor Neurological Disease Metabolic Disease
    Cinitapride (Standard) is the analytical standard of Cinitapride. This product is intended for research and analytical applications. Cinitapride is a nonselective 5-HT1 and 5-HT4 receptors agonist and a 5-HT2 and D2 antagonist. Cinitapride can be used in functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) research [1].
    Cinitapride (Standard)
  • HY-121562

    Others Neurological Disease
    SB 714786 is a potent and selective 5-hydroxytryptamine 1D (5-HT1D) receptor antagonist. It was developed from the previously reported series of dual 5-HT1 selective 5-hydroxytryptamine reuptake inhibitors (5HT1-SSRIs). SB 714786 is the first reported highly potent and selective 5-HT1D receptor antagonist, providing an extremely useful pharmacological tool for further understanding the role of 5-HT1 receptor subtypes. It has no or very low intrinsic activity against all three receptors. SB 714786 has pKi values of 6.5, 6.7, 9.1 and 6.5 for 5-HT1A, 5-HT1B, 5-HT1D and SerT receptors, respectively, showing high selectivity for 5-HT1D receptors. These properties make SB 714786 a potential tool compound for studying the function of 5-HT1D receptors and the treatment of related diseases.
    SB 714786
  • HY-B0121BS2

    GR 43175 free base-d5

    5-HT Receptor Isotope-Labeled Compounds Neurological Disease
    Sumatriptan-d5 is deuterated labeled Sumatriptan (HY-B0121B). Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research [1] .
    Sumatriptan-d5
  • HY-103151A

    5-HT Receptor Others
    CP94253 is a selective, orally active agonist for serotonin receptor 1B (5-HT1B), through competitive binding with iodocyanopindolol (ICP) to the 5-HT1 receptor. CP94253 binds to the 5-HT1B, 5-HT1A, 5-HT1D, 5-HT1C and 5-HT2 receptors, with Kis of 2, 89, 49, 860 and 1600 nM. CP94253 causes satiety, anorexia, weight loss and hyperlocomotion in rats model [1].
    CP94253
  • HY-100943
    Cinanserin hydrochloride
    1 Publications Verification

    SQ 10643

    5-HT Receptor Influenza Virus Infection Inflammation/Immunology
    Cinanserin hydrochloride (SQ 10643) is a potent, selective and highly affinity 5-HT2 receptor antagonist with a Ki of 41 nM. Cinanserin hydrochloride has a much higher binding affinity for the 5-HT2 than for the 5-HT1 receptor (Ki of 3500 nM). Cinanserin is also an inhibitor of 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro [1] .
    Cinanserin hydrochloride
  • HY-133828

    5-HT Receptor SARS-CoV Infection
    Cinanserin (SQ 10643) is a potent and selective 5-HT2 antagonist with Ki values of 41, 3500 nM for 5-HT2, 5-HT1, respectively. Cinanserin also is a SARS-CoV 3CL pro inhibitor with an KD value of 49.4, 18.2 µM for SARS-CoV 3CL pro, HCoV-229E 3CL pro, respectively. Cinanserin reduces systemic burn edema levels [1] .
    Cinanserin
  • HY-146201

    Phosphodiesterase (PDE) Others
    1 a /5-hydroxynitrile rubber 7 receptor antagonist (5-HT1 a k i = 8 nm, kb= 0.04 nm; 5-nitrile rubber 7K I = 451 nm, kb= 460 nm) has pde4b/pde7a inhibitory activity (PDE4B ic50= 80.4 μ M; Pde7a chip 50= 151.3 μ M)。 Compound 22 has a very good ability of passive penetration of biofilm and high metabolic stability in vitro. In addition, 22's pharmacological evaluation showed its pre cognitive and antidepressant properties in rat behavioral tests.
    PDE4B/7A-IN-1
  • HY-163101

    Platelet-activating Factor Receptor (PAFR) Leukotriene Receptor Inflammation/Immunology
    CP-96021 is a potent and orally available leukotriene D4 (LTD4 Ki=34 μM) / platelet activating factor (PAF Ki=37 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD4 and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC50 values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma [1].
    CP-96021
  • HY-10564
    Sarpogrelate hydrochloride
    1 Publications Verification

    MCI-9042

    5-HT Receptor Cardiovascular Disease
    Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis [1] .
    Sarpogrelate hydrochloride
  • HY-144764

    5-HT Receptor Neurological Disease
    5-HT1A antagonist 1 (compound 6f) is a potent and selective antagonist of 5-HT1A receptor, with a Ki of 35 nM. 5-HT1A antagonist 1 can be used for the research of CNS diseases [1].
    5-HT1A antagonist 1
  • HY-10564S

    MCI-9042-d3

    Isotope-Labeled Compounds 5-HT Receptor Cardiovascular Disease
    Sarpogrelate-d3 (hydrochloride) is the deuterium labeled Sarpogrelate hydrochloride. Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis[1][2][3].
    Sarpogrelate-d3 hydrochloride
  • HY-136621

    5-HT Receptor Neurological Disease
    5-HT1A modulator 2 hydrochloride, a derivative of 8-OH-DPAT (HY-112061), is a modulator of 5-HT1A with a Ki of 53 nM for 5-HT1A binding [1].
    5-HT1A modulator 2 hydrochloride
  • HY-162585

    5-HT Receptor Neurological Disease
    5-HT1AR agonist 1 (Compound A3) emerges as a relatively balanced multi-target activity profile, including 5-HT1AR agonist with an EC50 value of 34 nM, SERT reuptake ihibitor (IC50 =12 nM), NET reuptake inhibitor (IC50 =78 nM) and DAT reuptake inhibitor (IC50 =135 nM). 5-HT1AR agonist 1 performs significant antidepressant effects and exhibits excellent bioavailability and low clearance in mice, which is promising for research in the field of antidepressant drugs [1].
    5-HT1AR agonist 1
  • HY-100290

    5-HT Receptor Neurological Disease
    5-HT1A modulator 1 displays very high affinities for the 5HT1A, adrenergic α1 and dopamine D2 receptor with IC50s of 2 ±0.3 nM, 10 ± 3 nM and 40 ±9 nM, respectively.
    5-HT1A modulator 1
  • HY-162083

    Cannabinoid Receptor 5-HT Receptor Neurological Disease
    CB2R/5-HT1AR agonist 1 (Compound 2o) is an orally active partial agonist of the CB2 receptor (EC50=479.6 nM). CB2R/5-HT1AR agonist 1 is a full agonist of 5-HT1A receptor (EC50=2.7 μM). CB2R/5-HT1AR agonist 1 exhibits anti-anxiety and anti-depressive effects. CB2R/5-HT1AR agonist 1 possesses favorable pharmacokinetic properties [1].
    CB2R/5-HT1AR agonist 1
  • HY-101208

    5-HT Receptor Neurological Disease Inflammation/Immunology
    L694247 is a selective 5-HT1D agonist with the pIC50 values of 10.03, 8.64, 6.42, and 5.66 for 5-HT1D, 5-HT1A, 5-HT1C, and 5-HT1E receptors , respectively [1].
    L694247
  • HY-116908

    5-HT Receptor Neurological Disease
    SB-272183 is a selective 5-HT1A, 5-HT1B and 5-HT1D receptor antagonist. In addition, SB-272183 is also a potent and selective ligand for 5-HT1A, 5-HT1B and 5-HT1D receptors in human recombinant and native tissues with pKi values ??of 8.0, 8.1 and 8.7, respectively. SB-272183 can be used in antidepressant research [1].
    SB-272183
  • HY-124117

    5-HT Receptor Neurological Disease
    LY 278584 is a potent, highly selective 5-HT3 receptor antagonist with a Ki of 1.62 nM. LY 278584 has no activity on 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, or 5-HT2 receptors [1].
    LY 278584
  • HY-101698

    Alnitidan

    5-HT Receptor Neurological Disease Inflammation/Immunology
    Alniditan (Alnitidan) is a potent 5-HT1B and 5-HT1D receptors agonist, with IC50s of 1.7 nM and 1.3 nM for h5-HT1B and h5-HT1D receptors in HEK 293 cells, respectively. Alniditan has migraine-preventive effects [1] .
    Alniditan
  • HY-101698B

    Alnitidan dihydrochloride

    5-HT Receptor Neurological Disease Inflammation/Immunology
    Alniditan (Alnitidan) dihydrochloride is a potent 5-HT1B and 5-HT1D receptors agonist, with IC50s of 1.7 nM and 1.3 nM for h5-HT1B and h5-HT1D receptors in HEK?293 cells, respectively. Alniditan dihydrochloride has migraine-preventive effects [1] .
    Alniditan dihydrochloride
  • HY-103151

    5-HT Receptor Neurological Disease
    CP94253 hydrochloride is a potent and selective agonist of 5-HT1B receptor (Ki= 2 nM in a radioligand binding assay).Ki values for 5-HT1A, 5-HT1D, 5-HT1C and 5-HT2 receptors are 89, 49, 860, and 1600 nM respectively [1]. CP94253 hydrochloride is centrally active upon systemic administration in vivo .
    CP94253 hydrochloride
  • HY-B1658A

    (R)-Frovatriptan succinate hydrate; SB 209509 succinate hydrate; VML 251 succinate hydrate

    5-HT Receptor Neurological Disease
    Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research [1] .
    Frovatriptan succinate hydrate
  • HY-B1658B

    (R)-Frovatriptan succinate; SB 209509 succinate; VML 251 succinate

    5-HT Receptor Neurological Disease
    Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research [1] .
    Frovatriptan succinate
  • HY-123704

    5-HT Receptor Neurological Disease
    CGS-12066 (maleate) is a 5-HT receptor agonist. CGS-12066 has agonist effect for 5-HT1A , 5-HT1B ,5-HT1C and 5-HT1D with pEC50 values of 6.41, 7.56, 4.05 and 7.11, respectively. CGS-12066 can be used for the research of neurological disease [1].
    CGS-12066 maleate
  • HY-B0229

    BW-311C90; 311C90

    5-HT Receptor Endogenous Metabolite Neurological Disease
    Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine [1] .
    Zolmitriptan
  • HY-100942

    5-CT maleate

    5-HT Receptor Neurological Disease
    5-Carboxamidotryptamine maleate (5-CT maleate) is a potent 5-HT1A, 5-HT1B, 5-HT1D, 5-HT5 and 5-HT7 receptors agonist [1] .
    5-Carboxamidotryptamine maleate
  • HY-117575

    Others Neurological Disease
    WAY-100135 is a serotonergic compound belonging to the phenylpiperazine family, utilized in scientific research for its role as a strong antagonist of the 5-HT1A receptor and a partial agonist of the 5-HT1D receptor, with minimal activity at the 5-HT1B receptor.
    WAY-100135

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: